← EXACT SCIENCES CORP (EXAS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
EXACT SCIENCES CORP (EXAS)
Services-Medical Laboratories · market cap $20.0B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, best known for Cologuard, its FDA-approved stool DNA colorectal cancer screening test. The company generated $3.25B in revenue in 2025 and carries a $20B market cap, positioning it as a scaled commercial diagnostics business. Despite growing revenue, it has posted net losses in each reported year, with a $208M net loss in 2025.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Modified FOLFIRINOXimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Modified FOLFIRINOX | Phase 2 | Locally Advanced Pancreatic Adenocarcinoma |
Price & technical context
3-month
+3.2%
6-month
+95.8%
12-month
+129.6%
52-wk range
$40.31–$104.91
vs 50-day MA
+1.8%
vs 200-day MA
+41.2%
Realized vol
42.4%
Max drawdown
-45.7%
Daily closes through 2026-03-20. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EXAS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.